Ideas
Post-JPM dips can be bought
Pharma/biotech shares often fall after the JPM Healthcare Conference as event-driven buyers sell. If high-conviction names shake out after the event, that pullback can be a long-term buying opportunity, especially when presentations confirm the original investment thesis.
Gene therapy is next major theme
The speaker expects gene therapy to become the main 2026 pharma/biotech theme, with the weight shifting away from obesity. She cites improving gene-therapy data in obesity, including good safety, fat loss without muscle loss, and durable effects, and notes that Lilly has invested in Korean gene-therapy companies. Investors should study gene-therapy names throughout the year.
Biohaven-AimedBio partnership to watch
Biohaven is partnered with AimedBio, whose stock recently rose more than expected. The speaker flags Biohaven's JPM schedule as a place to watch for updates on that partnership.
US biotech broadly attractive
At the JPM Healthcare Conference, almost all US biotech companies are in an opportunity zone. The event creates discussions and potential deals, making US biotech broadly attractive.
Hanmi MASH data catalyst
Hanmi Pharmaceutical out-licensed efinopegdutide to MSD for MASH. MSD may present it at the JPM Healthcare Conference, and 2026 data release is likely. Because Hanmi has a history of license returns, the stock has not reflected this pipeline, so positive data could drive inflows. MASH treatments are nearing approval, and phase 2 data can support breakthrough or accelerated paths.
LCB84 J&J milestone catalyst
LigaChem Biosciences out-licensed LCB84 to J&J/Janssen. Phase 1 is likely complete, and in 2026 investors should watch whether J&J/Janssen names LCB84 as a key pipeline. If interest increases, the single-development option milestone could be a major catalyst and the speaker calls the name a top pick.
FDA breakthrough for MASH asset
The speaker says Altimmune received FDA breakthrough therapy designation for its MASH treatment despite limited phase 2 data. This means it may be able to seek approval based on phase 2 results and has a higher approval probability, making it a specific MASH regulatory catalyst to watch.
Lilly leads, expands into gene therapy
Eli Lilly is the highest-interest US company at the JPM conference, already dominating obesity and actively pursuing M&A and technology transfers. The speaker says Lilly will do well and is now expanding into gene therapy, making its partnering choices a key signal for the sector.
Gene therapy shuttle platform to watch
ABL Bio's shuttle platform can attach antibodies, peptides, or gene therapies, making it relevant to gene-therapy delivery. The speaker says its approach needs watching.
Obesity stocks less exciting now
Obesity remains a large and durable market, but from an equity perspective the theme has become less interesting because it has been played for over a year and biotech investors tend to price the next technology. Investors should not buy stocks just because they are in obesity; they should focus on differentiated solutions.
Lilly-backed gene therapy play
The speaker says OliX Pharmaceuticals is a Korean gene-therapy company using a modality similar to gene therapies with strong data. Lilly invested in OliX and Alzinomics, which validates the space. She advises watching OliX despite high volatility and taking a long-term chart view.
MASH data wave in 2026
MASH drug development is in late stages, with major phase 3 and other data readouts from many companies expected in 2026. FDA breakthrough designation allows some MASH drugs to seek approval based on phase 2 data, raising the commercial value of positive assets. The speaker says investors should keep watching MASH.
ADC remains major biotech theme
The speaker views ADC as a major 2026 biotech area requiring substantial research. Korean ADC names include LigaChem Biosciences as a leader, newly listed IntoCell, AimedBio, and traditional capital-rich R&D companies such as Celltrion. Investors should watch these ADC names.
Capital-rich ADC developer to watch
Celltrion is a traditional, capital-rich R&D company that also participates in ADC, making it a Korean ADC name to watch alongside LigaChem Biosciences and newly listed ADC companies.
This 3PRO TV (삼프로TV) video, published January 07, 2026,
features Kim Seon-ah
discussing XBI, Gene therapy, BHVN, AimedBio, US biotech, 128940.KS, 141080.KQ, ALT, LLY, 298380.KQ, THNR, 226950.KQ, MASH (NASH) therapeutics, ADC (antibody-drug conjugates), 068270.KS.
14 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Kim Seon-ah
· Tickers:
XBI,
Gene therapy,
BHVN,
AimedBio,
US biotech,
128940.KS,
141080.KQ,
ALT,
LLY,
298380.KQ,
THNR,
226950.KQ,
MASH (NASH) therapeutics,
ADC (antibody-drug conjugates),
068270.KS
